Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors

Besan H Alsaafeen¹Bassam R Ali^1*Eyad Elkord^2*

• ¹Department of Genetics and Genomics, United Arab Emirates University, Al-Ain, United Arab Emirates
• ²Department of Biosciences and Bioinformatics & Suzhou Municipal Key Laboratory of Biomedical Sciences and Translational Immunology, Xi'an Jiaotong-Liverpool University, Suzhou, China

Over the past few years, immune checkpoint inhibitors resulted in magnificent and durable successes in treating cancer; however, only a minority of patients respond favorably to the treatment due to a broad-spectrum of tumor-intrinsic and tumor-extrinsic factors. With the recent insights gained into the mechanisms of resistance, combination treatment strategies to overcome the resistance and enhance the therapeutic potential of immune checkpoint inhibitors are emerging and showing promising results in both pre-clinical and clinical settings. This has been derived through multiple interconnected mechanisms such as enhancing tumor immunogenicity, improving neoantigen processing and presentation in addition to augmenting T cell infiltration and cytotoxic potentials. In the clinical settings, several avenues of combination treatments involving immune checkpoint inhibitors were associated with considerable improvement in the therapeutic outcome in terms of patient's survival and tumor growth control. This, in turn, increased the spectrum of cancer patients benefiting from the unprecedented and durable effects of immune checkpoint inhibitors leading to their adoption as first-line treatment for certain cancers. Moreover, the significance of precision medicine in cancer immunotherapy and the unmet demand to develop more personalized predictive biomarkers and treatment strategies are also highlighted in this review.